bioAffinity Technologies (BIAF) – Investment Analysts’ Weekly Ratings Changes

bioAffinity Technologies (NASDAQ: BIAF) recently received a number of ratings updates from brokerages and research firms:

• 8/10/2026 – bioAffinity Technologies was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/2/2026 – bioAffinity Technologies was downgraded by Wall Street Zen from “hold” to “sell”.
• 7/25/2026 – bioAffinity Technologies was upgraded by Wall Street Zen from “sell” to “hold”.
• 7/20/2026 – bioAffinity Technologies had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 7/5/2026 – bioAffinity Technologies was downgraded by Wall Street Zen from “hold” to “sell”.
• 6/27/2026 – bioAffinity Technologies was upgraded by Wall Street Zen from “sell” to “hold”.

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.